Adherium Ltd. · ASX:ADR
Adherium — Q3 FY18 Earnings Presentation
12 slides from Adherium's earnings presentation, May 4, 2018
Slide 1: Investor Results Q3 FY18
Investor Results Q3 FY18 May 4, 2018
Slide 2: Forward Looking Statement
Forward Looking Statement The following material is of a general nature and has only been prepared as a presentation aid. This presentation does NOT contain all of the information that may be required for evaluating Adherium Limited ACN 605 352 510 (Adherium or the Company), its assets, prospects or
Slide 3: Corporate Highlights
Corporate Highlights A few of our Quarterly Highlights: • Revenue growth continues to be strong • Net cash use limited to $762K for quarter • SmartTouchTM for Symbicort® 510(k) clearance for OTC by US FDA • US based VP of Sales was hired • Adherium and Vitalus Health announce program to reach COPD p
Slide 4: Review Results
adherium% Review Results
Slide 5: Quarter 3 Cash Flows
Quarter 3 Cash Flows 3 months to Change % 3 months to December 31, March 31, 2018 2017 Receipts from customers $2.0m $0.6m 358% increase Staff costs $1.6m $2.2m 24% decrease Other operating cash outflows (net) $1.4m $1.9m 30% decrease Total operating cash outflows $1.0m $3.5m 72% decrease As at Chan
Slide 6: Execution and Guidance
adherium% Execution and Guidance
Slide 7: Quarterly Execution Review
Quarterly Execution Review • Shipped over 17,500 devices to AstraZeneca in the 9 months, with over 4,200 in Q3 FY18 • Over 19,100 devices shipped to the end of Q3 FY18 compared with 18,100 for all of FY17 • Revenue on plan to achieve guidance for FY18 full year • Received FDA 510(k) OTC clearance fo
Slide 8: Market Channel - OEM
OEM – Strategic Priorities • Increasing volume in existing Smartinhaler product lines by launching into new large markets • Expanding product range leveraging existing OEM partnerships (beyond Symbicort®) • Opportunistically evaluating new OEM distribution agreements OEM – Business Model • Innovatio
Slide 9: Market Channel - Direct to Consumer (DtC)
Direct to Consumer – Strategic Priorities • Focus only on US market (~40m Asthma and COPD patients) • Direct, digital only marketing • Highly targeted customer acquisition strategy • Subscription offering Direct to Consumer – Business Model Market Channel • Online – using Facebook, Instagram, Google
Slide 10: Market Channel - Direct to Payer (DtP)
Direct to Payer – Strategic Priorities • Launch in US market to have access to ~40m patient market size • B2B sales with initial focus on smaller, self-contained insurance systems for more rapid adoption and in market economic validation • Larger self-insured corporations focused on lowering cost of
Slide 11: Summary
Summary Q3 Summary Delivering predictable results to the metrics while establishing our new market channels. OEM Commercial sensor shipments are progressing to plan, and innovation and engineering services are focused on expanded list of drugs. Next step is for sensor shipments to increase. Prepared
Slide 12: Thank You
adherium% Adherium THANK YOU